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Glioblastoma multiforme (GBM) is the most common and aggressive primary neoplasm of the brain. Poor prognosis is mainly attributed to
tumor heterogeneity, invasiveness, and drug resistance. microRNA-based therapeutics represent a promising approach due to their ability to inhibit
multiple targets. In this work, we aim to restore the oncosuppressor activity ofmicroRNA-34a (miR-34a) in GBM.We developed a cationic carrier
system, dendritic polyglycerolamine (dPG-NH2), which remarkably improves miRNA stability, intracellular trafficking, and activity. dPG-NH2
carryingmaturemiR-34a targets C-MET,CDK6,Notch1 andBCL-2, consequently inhibiting cell cycle progression, proliferation andmigration of
GBM cells. Following complexation with dPG-NH2, miRNA is stable in plasma and able to cross the blood–brain barrier. We further show
inhibition of tumor growth following treatment with dPG-NH2–miR-34a in a human glioblastoma mouse model. We hereby present a promising
technology using dPG-NH2–miR-34a polyplex for brain-tumor treatment, with enhanced efficacy and no apparent signs of toxicity.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tumor. Its aggressive nature and evasiveness to treatments make
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therapy and anti-angiogenic agents usually remains palliative.2,3
Due to GBM's diffusive and invasive nature, complete removal
of the tumor is impossible by conventional surgery and hence
results in high recurrence rate.4 In almost all cases, recurrent
tumors are resistant to all available treatments.5-8 Hence, novel
agents targeting relevant pathways are desperately needed. The
heterogeneous nature of GBM and anatomic complexities
crossing the blood–brain barrier9,10 make its treatment a difficult
goal. Moreover, the molecular mechanisms of drug resistance
displayed by GBM are only partially understood. Cancer cell
proliferation, growth and death are regulated by intricate
networks of signaling pathways. Inhibiting any one specific
pathway mostly results in the activation of compensating
mechanisms. Hence, we propose to target multiple biological
pathways in order to effectively impede cancer progression and
recurrence, and overcome drug resistance.
MicroRNAs (miRNAs, miRs) are master regulators of the
genome that play a key role in the regulation of cell cycle,is an open access article under the CC BY-NC-ND license
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upregulation of miRNAs have been recently implicated in the
development of GBM.11,12
The therapeutic use of miRNAs has gained much attention
because their mechanisms of action are in line with our current
perception of cancer as a multiple pathways-associated disease.
miR-34a was originally uncovered as a potential tumor suppressor
that is downregulated and induces apoptosis in neuroblastoma
cells.13 Shortly afterwards, a few studies almost simultaneously
reported that miR-34a functions as a transcriptional target of
p53.14-17 Since then, a number of studies have addressed the
deregulation of miR-34a in various cancers including colon,
leukemia, lymphoma, brain, bone, skin, prostate, ovary, pancreas,
liver and lung.18-25 miR-34a was found to affect tumor cell
apoptosis, senescence, proliferation and invasion, via regulation of
hundreds of predicted mRNA targets including CDK6, C-MET,
Notch1 and Bcl-2.13,16,18,20,26,27 Li et al28 showed that miR-34a is
downregulated in GBM and inhibits cell proliferation, survival,
migration and invasion. Following transfection withmiR-34a prior
to inoculation into mice, GBM cells formed smaller xenografts.28
miR-34a overexpression also inhibits various malignancy end-
points in glioma stem cells, inducing glioma stem cell
differentiation.29 This important work suggested that miR-34a
plays a key tumor suppressive role in GBM.28,29 We therefore aim
to evaluate the therapeutic potential of miR-34a in GBM. Mirna
Therapeutics' lead product candidate, MRX34, designed to deliver
miR-34a mimic, is currently in Phase 1 clinical trial for
unresectable liver cancer and other hematological malignancies
(http://www.mirnarx.com/pipeline/mirna-MRX34.htmL).
We developed dendritic polyglycerolamine (dPG-NH2), a
polyglycerol-based nanocarrier to deliver small interfering RNA
(siRNA) and miRNA to tumors in vivo.30-33 dPG-NH2 is a
cationic hyperbranched polymer, which improves siRNA
stability, intracellular trafficking, silencing efficacy, and accu-
mulation in the tumor environment due to the enhanced
permeability and retention effect. dPG-NH2 exhibited low
cytotoxicity and high efficacy in delivering active siRNA into
cells and successfully silenced a luciferase gene, ectopically
overexpressed in a human GBM cell line.33
In the current work, we show that dPG-NH2–miR-34a polyplex
restores the tumor suppressing function of miR-34a in GBM.
Treatment of several GBM cells with dPG-NH2–miR-34a
polyplex inhibits cells' proliferation and migration, potentially
via the direct modulation of miR-34a-downstream targets CDK6,
C-MET, Bcl-2 and Notch1. More significantly, miR-34a restora-
tion led to remarkable reduction in tumor growth in amousemodel
of human GBM. Restoration of miR-34a tumor suppressor activity
may hold significant promise as a novel molecular therapy for
human GBM. The ability of dPG-NH2–miR-34a to impact
multiple cellular pathways also suggests that miR-34a can act
synergistically with conventional, cytotoxic therapies.Methods
Ethics statement
All animal experiments were approved by Tel-Aviv Univer-
sity animal care and use committee (IACUC) and conducted inaccordance with NIH guidelines for humane care. Experiments
involving human tissues were performed following informed
consent of patients and approved by our institutional review
board for research involving human subjects (IRB).
dPG-NH2 synthesis
Synthesis of dendritic polyglycerol (dPG-NH2) analogues
was executed according to a three-step protocol as previously
reported34-36 (brief description in Supplementary Material).
Electrophoresis mobility shift assay (EMSA)
The optimal ratio for the polyplex formation was studied as
described previously.33
psiCHECK luciferase reporter assay
The activity of a dPG-NH2–miR-34a polyplex toward a
consensus target sequence cloned into the 3′-untranslated region
(3′-UTR) of Renilla luciferase was monitored by a dual
luciferase assay in U-87 MG, U251 and U373 GBM cells.
More detailed description of the assay can be found at the
Supplementary Material section.
Physico-chemical characterization of the polyplex
Dynamic light scattering (DLS) and zeta potential determi-
nation were performed using a ZetaSizer Nano ZS instrument
(λ = 633 nm; Malvern Instruments Ltd., UK). Scanning electron
microscope (SEM) images were taken by Quanta 200 FEG
Environmental SEM (FEI, Oregon, USA) at high vacuum and
10.0 kV. Samples preparation is described in the Supplementary
Material section.
Patient-derived human primary glioblastoma cells
Fresh GBM specimens were obtained from Tel Aviv Medical
Center (Tel-Aviv, Israel). Each tumor specimen was cut to 2 mm
diameter pieces and cultured in DMEMmedium containing 20%
fetal bovine serum (FBS), 1% L-glutamine, 1% penicillin and
streptomycin. Following continuous media replacement, viable
cancer cells remained attached to culture plates and kept growing
in culture, while stroma and cell debris were washed away.
Confocal microscopy
microRNA-34a (miR-34a) (50 pmol) (Biospring, Germany)
was mixed with FITC-labeled dPG-NH2 (100 pmol) in
serum-free medium, incubated for 20 min at RT, and then
added to U-87 MG cells previously seeded on cover glasses.
Twenty four hours later, cells were fixed with 4% paraformal-
dehyde and immunostained with anti-EEA1 (BD Biosciences)
and anti-LAMP1 (Cell Signaling, USA) antibodies, followed by
rhodamine-labeled secondary antibodies (Jackson, USA). Cover
glasses were mounted by Vectashild (Vector Laboratories, USA)
and analyzed by Leica TCS SP5 confocal imaging (Leica
Microsystems, Germany).
Real time PCR
RNA samples from A172, U-87 MG and T98 human GBM
cell lines transfected with 200 nM miR-34a or negative control
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harvested 24 h later were reverse transcribed (miSCript II RT,
Qiagen) and miR-34a expression levels were evaluated by
miSCript miRNA PCR assay (Qiagen) according to the
manufacturer's protocol. Target genes expression levels were
assessed by SYBR green real time PCR (SensiFAST™ SYBR,
Bioline; StepOne plus, Life Technologies). Sequences of primers
used are detailed in the Supplementary Material section.
Cell proliferation assay
Human GBM cell lines and patient-derived primary glioblas-
toma cells were treated with dPG-NH2–miR-34a or
dPG-NH2-NC miR (200 nM dPG-NH2, 100 nM miRNA), or
left untreated. Four days later, cells proliferation was assessed by
Coulter Counter (Beckman Coulter).
Cell cycle analysis
U-87 MG cells were transfected with dPG-NH2–miR-34a,
dPG-NH2–NC-miR (100 nM miRNA, 200 nM dPG-NH2) or
left untreated. Following 72 h cells were labeled with propidium
iodide (25 μg/mL), 0.1% Triton X-100 and DNase-free RNase A
(5 μg/mL) and incubated in the dark on ice for 30 min. The
stained cells (1 × 106) were then analyzed for DNA content with
a flow cytometer (FACScalibur, Becton–Dickinson).
Migration assay
Cells migration was evaluated using transwells chambers
with pore size of 8 mm (Costar Corp., Corning, NY, USA). U-87
MG and A172 cells were treated with dPG-NH2–miR-34a,
dPG-NH2–NC-miR (200 nM miR) or left untreated. GBM cells
(48 h after treatment) or untreated HUVEC were seeded at the
upper chamber of transwells. Following 2 h, 10%
FBS-containing media (for GBM cells) or GBM conditioned
media (for HUVEC) were added to the lower chamber. Cells
were allowed to migrate to the lower chamber for 4 h, followed
by fixation and staining (Hema 3, Fisher HealthCare).
More detailed protocol can be found in the Supplementary
Material section.
Stability of microRNA in plasma
50 pmol of miR-34a, either naked or complexed with
dPG-NH2 (N/P 9) was incubated with mouse plasma (Sigma),
at 37 °C for the indicated times, followed by 15 min at room
temperature with or without sodium heparin (0.25 IU final
conc.). Samples were analyzed by electrophoresis.
Cytokines induction assay
Peripheral blood mononuclear cells (PBMCs) were incubated
with dPG-NH2, miR-34a and dPG-NH2–miR-34a for 4 h at
37 °C. Lipopolysacharides (Sigma) were used as positive control
(1 μg/mL), PBS as negative control. Upon incubation, RNA was
isolated from cell pellets and reverse transcribed using EZ-RNA
II isolation kit and EZ-first strand cDNA synthesis kit
(Biological industries). TNF-α and IL-6 levels were assessed
by SYBR green based real-time PCR and normalized to GAPDH
(primers in Supplementary Material).Animal studies
U-87 MG human cells (1 × 106) were injected subcutane-
ously to 6- to 8-week-old male SCID mice (Harlan Laboratories,
Israel). Tumor size was measured using caliper and volume was
calculated using standard formula (length × width2 × 0.52).
Once tumors reached the size of 50 mm3, mice were injected
intratumorally with PBS, dPG-NH2–miR-34a and dPG-NH2–
NC-miR (4 mg/kg miRNA, 10 mg/kg dPG-NH2) on days 0, 3
and 6. Animals were monitored twice a week for general health,
body weight and tumor volume.
Intracranial GBM cells inoculation
SCID mice anesthetized with ketamine–xylazine were
secured to a stereotaxic device and a 1-cm incision was made
on the skull midline between the ears. A small hole was drilled
1.5 mm left, 0.5 mm anterior and 2.5 mm ventral to the bregma.
mCherry-labeled U-87 MG cells (2 × 105) were slowly
inoculated and incision was closed by wound clips. Animals
were monitored twice a week for general health and body weight.
Tumor growth was followed by Maestro CRI™ intravital
non-invasive imaging.
Polyplex accumulation follow-up and half-life in plasma
Cy5-labeled dPG-NH2–miR-34a (2 mg/kg miRNA, 5 mg/kg
dPG-NH2) was injected intravenously to 6- to 8-week-old male
SCID mice bearing subcutaneous and intracranial U-87 MG, and
to non-tumor bearing mice. Polyplex accumulation in tumor
and organs was followed with Maestro CRI™. One hour and
five hours after administration, mice were euthanized and
intracardially perfused with saline, and tumor and organs were
resected and analyzed for Cy5-dPG-NH2 accumulation. Blood
samples were taken from the mice orbital sinus on different time
points following polyplex injection. Plasma was isolated and
fluorescence intensity (λEx = 630 nm, λEm = 670 nm) was
measured using SpectraMax M5 plate reader.Results
Synthesis and physicochemical characterization of dPG-NH2–
miR-34a polyplex
Hyperbranched polyglycerol with high amine loading
(Figures 1, A, S1) was synthesized, as previously reported.33
To assess the capability of dPG-NH2 to complex miRNA, we
incubated several amounts of the polymer with a constant
amount of miR-34a and analyzed the efficacy of the polyplex
formation by electrophoresis mobility shift assay (Figure 1, B).
Similar results were obtained with dPG-NH2–NC-miR
polyplex (data not shown). While a neutral polyplex formed at
N/P 2.5, maximal miR-34 activity and minimal cytotoxicity
with dPG-NH2–miR-34a polyplex were achieved at N/P 9
(Figure 1, C and D), therefore this ratio was selected for all
consecutive experiments.
dPG-NH2–miR-34a polyplexes were analyzed for their
hydrodynamic diameter, zeta potential and morphology using
DLS analyzer and SEM respectively. Neutralization of the
Figure 1. Physicochemical characterization of dPG-NH2-miR-34a polyplex. A. Schematic structure of dPG-NH2-miRNApolyplex. B.ElectrophoresisMobility Shift
Assay with dPG-NH2-miR-34a at N/P ratios of 0, 0.4, 0.9, 2.5, 4.5 and 9. C-D. U-87 MG glioblastoma cells were treated with dPG-NH2-miR-34a or
dPGNH2-NC-miR at N/P ratios of 2.2, 4.5 and 9 at dPG-NH2 concentrations of 100, 200 and 400 nM, respectively. C. Activity of dPG-NH2-miR polyplexes at
differentN/P ratioswasmonitored by a dual luciferase assay. D. Cells viabilitywas assessed byXTTproliferation assay. E. Zeta potential. F. Size distribution. G. SEM
image. H. Table summarizing zeta potential, hydrodynamic diameter and average diameter of dPG-NH2-miR-34a polyplex (N/P 9).
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Figure 2. Intracellular trafficking of dPG-NH2–miRNA polyplex in U-87 MG cells. (A) Co-localization of FITC-labeled dPG-NH2 miRNA polyplex with
EEA1 and LAMP1. Confocal images following 24 h incubation of cells with FITC-dPG-NH2 miRNA polyplex. (B)Quantitative analysis using Imaris software
(Bitplane AC, Switzerland). Data represent mean ± stdev. from five different fields.
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with dPG-NH2 was confirmed by zeta potential measurements.
Mixture of miRNA with dPG-NH2 at pH 7.4, yielded polyplexes
with positive charges. Surface charge values, hydrodynamic
volume and diameter of dPG-NH2–miRNA polyplex at N/P ratio
of 9 were determined (Figure 1, E-H). The measured particle's
hydrodynamic diameter was 113.9 ± 35.73 nm with a polydis-
persity index of 0.063. Such low size dispersity of the polyplexes
evidences the strong interaction and stability of the complex
between dPG-NH2 and miR-34a. The size distribution showed a
high correlation with the diameter obtained in the SEM analysis
(100 ± 17 nm). This diameter reflects assemblies of several
dPG-NH2–miRNAs and is in accordance with previouslyreported data.31 The measured zeta potential was slightly
positive (16.4 ± 3.60 mV) as expected.33
dPG-NH2–miR-34a polyplex internalizes into GBM cells via
endocytosis
Using confocal microscopy, we followed miRNA internali-
zation to human GBM cells, and consequently confirmed the
high efficacy of FITC-labeled dPG-NH2 as a nanocarrier for
small RNA molecules. In order to determine dPG-NH2 polyplex
internalization mechanism, we performed colocalization studies
with subcellular markers: early endosome antigen 1 (EEA1) and
lysosomal-associated membrane protein 1 (LAMP-1). High
Figure 3. dPG-NH2–miR-34a polyplex-treated human GBM cells express higher levels of miR-34a and lower levels of its target genes. (A-E) A172, U-87 MG
and T98 human GBM cells were treated with dPG-NH2–miR-34a, dPG-NH2–NC-miR or left untreated. Twenty-four hours later, RNA was isolated and qPCR
was performed to evaluate miR-34a, C-MET, CDK6, Notch1 and Bcl-2 expression levels. ***P value ≤ 0.01, **P value ≤ 0.05 related to untreated control and
to NC-miR.
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Figure 4. dPG-NH2–miR-34a polyplex inhibits GBM miR-34a activity, cell cycle progression and cell survival. (A) Activity of a dPG-NH2–miR-34a polyplex
monitored by a dual luciferase assay in U-87 MG, U251 and U373 GBM cells. (B-D) GBM cells were treated with dPG-NH2–miR-34a or dPG-NH2–NC-miR
(100 nM miR). (B) U-87 MG cells were analyzed by flow cytometry 72 h following treatment with polyplex. (C-D) Four days later, cell proliferation was
assessed by Coulter Counter. ***P value ≤ 0.01, **P value ≤ 0.05 related to untreated control and/or NC-miR. (C) U-87 MG, A172 and T98G human GBM
cell lines. (D) Human patient-derived GBM cells.
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LAMP1 markers (Figure 2), confirmed that their cellular uptake
is mediated by endocytosis via the endosome–lysosome path.
dPG-NH2–miR-34a polyplex-treated human GBM cells express
higher levels of miR-34a and lower levels of its target genes
miR-34 regulates several processes that promote cancer
development through downregulation of their target mRNAs. As
of today, more than 77 miR-34 targets have been validated,
including MET,17,20 CDK6,26,37 Notch138,39 and Bcl-2.17,40,41
Following treatment with dPG-NH2–miR-34a, we observed
remarkably higher levels of miR-34a and lower expression levels
of its target genes: C-MET, CDK6, Notch1 and Bcl-2 in several
human GBM cell lines (Figure 3). This means not only that
miR-34a is effectively internalized into the cells cytoplasm, but it
is also released from the dPG-NH2 carrier, escaping from the
endosome. Then, it binds to its target sequences in the cytoplasm
and successfully inhibits gene expression.dPG-NH2–miR-34a polyplex inhibits GBM miR-34a activity,
cell cycle progression and cell survival
We further evaluated the activity of miR-34a mimic,
delivered to the cell cytoplasm by dPG-NH2, using psiCHECK
(Promega™) plasmid constructs. psiCHECK™-2-based con-
struct was prepared, containing one copy of the full target
(nucleotide sequence fully complementary to the miR-34a guide
strand). Results showed a remarkable downregulation of the
miR-34a target sequences following treatment of several GBM
cells with dPG-NH2–miR-34a polyplex (Figure 4, A). Moreover,
miR-34a overexpression induced cell cycle arrest in S-phase
(Figure 4, B) and inhibited viability and proliferation of human
GBM cell lines (Figure 4, C). Further support to the remarkable
anti-tumorigenic effect of dPG-NH2–miR-34a on GBM can be
found in Figure 4, D that shows reduced viability following
treatment with miR-34a polyplex in fresh GBM cells derived
from three different human patients. These findings demonstrate
that miR-34a mimic delivered to the cell cytoplasm by dPG-NH2
Figure 5. dPG-NH2–miR-34a polyplex inhibits migration of GBM cells toward serum and migration of endothelial cells toward GBM cells. Representative
images and quantification of migration experiments. (A) U-87 MG. ***P value ≤ 0.01, **P value ≤ 0.05 related to control and to NC-miR. (B) A172 cells.
(C) Human umbilical vein endothelial cells (HUVEC) toward conditioned media (C.M.) from GBM cells treated with dPG-NH2–miR-34/NC-miR polyplex.
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of miR-34a in GBM.
dPG-NH2–miR-34a polyplex inhibits migration of GBM cells
toward serum and migration of endothelial cells toward
conditioned media (CM) from GBM cells
Some of the known targets of miR-34a, like C-MET, are
directly involved in the regulation of cell migration, a highly
integrated, multi-step process that plays an important role in
cancer progression. Therefore, we evaluated the effect of
dPG-NH2–miR-34a polyplex on the invasion ability and
angiogenic potential of GBM cells. We found a remarkable
inhibition in the ability of GBM cells to migrate toward serum, as
well as the ability of endothelial cells to migrate toward CM from
GBM cells (Figure 5). Images of experiments represented in B
and C are shown in the supplementary information (Figure S2).
dPG-NH2–miR-34a polyplex is stable in plasma and do not
induce an immune response ex vivo
The relative stability of dPG-NH2–miR-34a polyplex was
evaluated by measuring miRNA release in the presence of the
competing polyanion heparin. Heparin, capable of displacing
RNA from polycation/RNA complexes, was chosen as a modelsubstance for this assay. The lowest concentration of heparin
required for miRNA displacement to occur provides an
estimation of the complex stability against polyanions.42
Following incubation of dPG-NH2–miR-34a polyplex with
increasing levels of heparin, we found that the level required
for miRNA release from the polyplex is 0.15 IU (International
Units)/20 μl reaction volume (Figure S3). This equals to 750 IU/
100 ml, while the average heparin levels in human plasma are
15 IU/100 ml.43 We next evaluated the integrity of the polyplex
versus that of the naked miRNA following incubation with
murine plasma. Summarizing the results presented in Figure 6, A,
we may conclude that dPG-NH2 confers good protection to
miRNA against plasma-induced degradation.
One additional important aspect for successful miRNA
delivery is preventing a robust adverse effect such as a cytokines
induction, lymphocyte activation or interferon response. Un-
modified duplex siRNA/miRNA may be recognized by the
immune system as an unwanted invader and trigger an immune
response. The miR-34a mimic used in the described work was
chemically modified at the 2′ position of ribose (2'-O-Methyl),
to block recognition by Toll-like receptors (TLRs) and thwart the
immune response. However, recent reports indicate that cationic
polymers like dPG-NH2 can potentially activate significant
immunological activity mediated by TLRs.44 In order to address
Figure 6. miR-34a and dPG-NH2–miR-34a polyplex physiological characterization. (A) Naked miR-34a and dPG-NH2–miR-34a were incubated at 37 °C in
mouse plasma, with or without heparin, and analyzed by gel electrophoresis. (B) Tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6) cytokines
secreted from human PBMCs following treatment with dPG-NH2, miR-34a or dPG-NH2–miR-34a (concentration in nM). Lipopolysaccharide (LPS) was used
as positive control, PBS as negative control.
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dPG-NH2–miR-34a polyplex on TNF-α and IL-6 cytokines
secretion from human peripheral blood mononuclear cells
(PBMCs). The results show no IL-6 and a moderate TNF-α
stimulation (Figure 6, B), suggesting no major activation of
immune response by dPG-NH2 or miR-34a.
dPG-NH2–miR-34 polyplex reaches both subcutaneous and
orthotopically inoculated glioblastoma tumors following systemic
administration
In order to evaluate the feasibility of systemic administration
of polyplex to treat GBM tumors, we followed the accumulation
of fluorescently labeled dPG-NH2–miR-34 in both subcutaneous
and intracranially inoculated GBM tumors (Figure 7, A and B,
respectively). Cy5-labeled dPG-NH2 complexed with miR-34a
was injected intravenously (i.v.) to mice bearing U-87 MG
human glioblastoma. The polyplex reached the tumor site within
5 min. dPG-NH2–miR-34a was capable of crossing the
compromised blood–brain barrier at the tumor site and reach
the GBM, although it was not accumulated there for long
(Figure 7, B). Thirty minutes following intravenous administra-tion, the level of Cy5-labeled polyplex localized in the
intracranial tumor was considerably reduced, suggesting its fast
clearance. In the subcutaneous tumor the Cy5-labeled polyplex
was retained for a slightly longer time. Probably due to its larger
size, the subcutaneous tumor displayed a more robust EPR
(enhanced permeability and retention) effect, as opposed to the
intracranial tumor. However, as clearly seen from the PK
experiment, shown in Figure 7, C, the polyplex has a very short
t1/2 in the plasma (4 min). It seems enough for some
extravasation into the tumor, however, the polyplex also
accumulated in reticuloendothelial system (RES) organs (lung
and liver). Subsequently, we are now working on the
development of a second generation of dPG-NH2 that will
hopefully be able to increase the accumulation and retention time
of the polyplex at the tumor site and minimize its presence in
normal tissues.
dPG-NH2–miR-34a polyplex inhibits GBM tumor growth in vivo
Following our findings that after systemic administration, the
polyplex reaches the tumor site but is rapidly cleared, we decided
to evaluate dPG-NH2 as a prototype miRNA nanocarrier for
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Figure 8. dPG-NH2–miR-34a polyplex inhibits U-87 MG tumor growth. (A) Tumor growth. (B) Kaplan–Meier analysis following 3 consecutive treatments
(marked by arrows inA) with dPG-NH2–miR-34a (miR-34a), dPG-NH2–NC-miR (NC-miR), or PBS. Data in tumor volume graph represent mean ± s.e.m. For
miR-34a treated toward NC-miR treated mice, P b 0.05 on days 20 to 30, P b 0.01 on days 32 to 62.
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to evaluate its potential to restore the tumor suppressing function
of miR-34a in GBM, following intratumoral administration of
dPG-NH2–miR-34a. U-87 MG human GBM cells were
subcutaneously inoculated in SCID mice. Once palpable tumors
developed, 10 mg/kg dPG-NH2 complexed with 4 mg/kg
miR-34a, NC-miR, or PBS was injected intratumorally, in line
with our previous study,33 with a slight adjustment to the optimal
N/P ratio of the new dPG-NH2–miRNA polyplexes (Figure 1).
According to the same study, the silencing effect of luciferase
siRNA delivered intratumorally with the same vehicle lastedFigure 7. Systemically-administered dPG-NH2–miR-34a polyplex accumulates in
was injected intravenously (i.v.) to mice bearing subcutaneous (A) and intracrani
miR-34a in the tumor was followed via intravital non-invasive imaging (Maestro C
tumors and organs were resected and imaged. Cy5-polyplex distribution in tumor a
% of Cy5 fluorescence in mCherry-labeled (U-87 MG tumor) area. (C) Half
non-tumor-bearing mice. Polyplex levels were monitored in blood samples tak
630 nm, λEm = 670 nm) was measured using SpectraMax M5 plate reader and isroughly for 3 days.33 Therefore, dPG-NH2–miRNA polyplex
was administered every 3 days.
As shown in Figure 8, A, a substantial tumor growth
inhibition was achieved, following 3 consecutive treatments
with dPG-NH2–miR-34a polyplex. While tumors in mice treated
with PBS reached the size of 1.2 cm3 around day 15, tumors
treated with dPG-NH2–miR-34a polyplex grew to that size
almost 35 days later. No weight loss or deterioration in general
health and behavior was observed.
Survival was significantly prolonged in the miR-34a-treated
mice. While the median survival for the PBS-treated group andglioblastoma tumors. (A-B) Cy5-dPG-NH2 (blue) complexed with miR-34a
al mCherry-labeled (B) U-87 MG tumors. Accumulation of Cy5-dPG-NH2–
RI™), quantified and plotted in a graph (in vivo). Mice were euthanized, and
nd organs are plotted in a graph (ex vivo). Percent colocalization represents the
-life of polyplex in plasma. Cy5-dPG-NH2–miR-34a was i.v. injected to
en from mice at several time points (n = 3). Fluorescence intensity (λEx =
plotted in a graph ± stdev.
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for the dPG-NH2–miR-34a treated group it was 55 days
(Figure 8, B).
Some non-specific anti-tumor activity was observed follow-
ing treatment with dPG-NH2–NC-miR polyplex. Unfortunately,
although several sequences were evaluated, we were not able to
generate a completely inert negative control. We expect to
reduce the non-specific effects of the NC-miR polyplex
after optimization of the formulation that will hopefully
enable to deliver lower doses of miR and achieve a maximal
therapeutic effect.Discussion
Poor prognosis for GBM is mainly attributed to undefined
tumor margins, critical location of the tumor mass and presence
of chemo- and radio-resistant tumor cells.45,46 Tumor heteroge-
neity is one of the main causes for drug resistance. Therefore,
miRNA-based therapeutics represent a promising approach that
can potentially overcome resistance mechanisms by inhibiting
multiple targets. miRNAs are dysregulated in almost all solid and
hematological malignancies. Several miRNAs that play impor-
tant roles in glioma has been discovered to date.47 Increased
understanding of miRNA role in glioma biology has led to the
approach of restoring normal miRNA expression and function
and improving the prognosis of glioma patients.
Altered modulation of drug response mediated by miR-34a
has been reported in a number of cellular models, including
GBM. miR-34a is a key regulator of tumor suppression,
downregulated in human glioma tumors as compared to normal
brain, and in mutant-p53 gliomas as compared to wild type-p53
tumors.48 Therefore, restoring the oncosuppressor miR-34a
provides a promising strategy against GBM. However, despite
the interest in the use of miR-34a as new anticancer agent, the
delivery issue represents a major obstacle. Reaching the right
target in the cancer cell cytoplasm still remains the Achilles' heel
of miRNA-based treatments. miRNA molecules are rapidly
degraded in biological fluids, poorly taken-up into cells and
homogeneously distributed throughout the body.49 Here we
show that we were able to stabilize the miRNA when complex-
ing it with our nanocarrier as compared to the free miRNA
incubated in plasma (Figure 6, A). We hereby show, for the first
time, successful delivery of miR-34a to human GBM cells both
in vitro and in vivo using dPG-NH2. dPG-NH2 formed a stable
complex with miRNA (Figure 1), of circa 100 nm size and zeta
potential of 16.4 mV, at N/P 9, that showed optimal activity.
dPG-NH2–miR-34a polyplex was successfully internalized
into the cytoplasm of human GBM cells via the
endosome-lysosome system (Figure 2), leading to increased
expression levels of miR-34a followed by downregulation of a
set of essential target genes: C-MET, CDK6, Notch1 and BCL-2
(Figure 3). C-MET is a receptor tyrosine kinase that activates a
wide range of cellular signaling pathways, including those
involved in proliferation, motility, migration and invasion. It has
been found to be aberrantly activated in human cancers via
mutation, amplification or protein overexpression.50 CDK6, a
cell cycle regulator, is significantly upregulated in glioma cells,and its elevated expression correlates well with the grade of
glioma malignancy.51 CDK6 knockdown dramatically inhibits
proliferation and survival of tumor cells and reduces the
expression level of drug resistance genes such as Multidrug
Resistance (MDR) and Multidrug Resistance associated Protein
(MRP).51 The Notch signaling pathway is involved in cell fate
decisions during normal development and in the generation of
several cancers.52 Notch signaling is activated in primary
GBM53 and it plays an important role in the cellular response
to hypoxia and angiogenesis,54 two key processes in the
development of human gliomas.55 BCL-2 has been widely
characterized ant it is known to block programmed cell death
rather than promote proliferation.56 BCL-2 was further shown to
play an additional role in the malignant phenotype of glioma
cells, that is, to enhance migration and invasion by altering the
expression of a set of metalloproteinases and their inhibitors.57
The four target genes evaluated here were previously established
as transcriptional targets of miR-34a that play key roles in glioma
cells.28 In our study, we demonstrate that they are all tightly
regulated by dPG-NH2–miR-34a polyplex.
dPG-NH2–miR-34a polyplex treatment further induced a
substantial inhibition of miR-34a-driven luciferase activity. Not
surprisingly, G1/S cell cycle arrest and decreased cell survival in
several human glioblastoma cell lines were observed. Remark-
able inhibition in cells survival and proliferation following
treatment with dPG-NH2–miR-34a was also measured in human
patient-derived GBM cells (Figure 4). This last finding may lead
to a higher correlation with clinical outcomes compared to
conventional cell line-derived models. Determining the function
or phenotype of patient-derived GBM cells following treatment
will hopefully lead to more comprehensive knowledge of tumor
development as well as mechanisms of resistance that are often
found in the clinic.
Moreover, dPG-NH2–miR-34a polyplex led to reduced
migration of GBM cells toward serum and migration of
endothelial cells toward glioblastoma cells (Figure 5). These
findings imply not only anti-tumorigenic but also anti-metastatic
activity of the polyplex. The above data shows that dPG-NH2 is a
promising nanocarrier, which not only neutralizes the negative
charge of miRNA, crosses the cell membrane and releases the
active miRNA into the cell cytoplasm; but also shields the
miRNA molecule against degradation by proteases.
Our polyplex successfully reached both subcutaneous and
intracranial GBM tumors following intravenous administration
(Figure 7). As previously demonstrated,58 the blood–brain
barrier in GBM tumors is hyperpermeable, enabling extravasa-
tion of polyplexes. Nevertheless, dPG-NH2–miR-34a was also
detected in healthy organs and most of it was found in the
kidneys within a few hours on its way for rapid clearance. We
therefore present dPG-NH2 as a prototype miRNA nanocarrier
for local delivery in its current structure and formulation.
Substantial tumor growth inhibition was achieved and mouse
survival was remarkably prolonged following local treatment of
GBM with dPG-NH2–miR-34a polyplex (Figure 8), while no
weight loss occurred. We further observed some anti-tumor
activity of dPG-NH2–NC-miR polyplex. Adding exogenous
miRNA to the system can result in repression of non-
physiological target mRNAs since miRNA–target interaction is
2213P. Ofek et al / Nanomedicine: Nanotechnology, Biology, and Medicine 12 (2016) 2201–2214strongly concentration-dependent.59 Optimizing the effective
dose that will not induce off-target effects is in our future plans.
dPG-NH2 can be used as an effective delivery for miR-34a
and other miRNAs for the local treatment of GBM. When
injected intravenously, this polyplex is rapidly cleared from the
circulation and also reaches the reticuloendothelial system (RES)
including organs such as the liver and the lung. In order to exploit
this nanocarrier further for systemic administration, we are
currently working on increasing its size and its ability to
overcome the immune system by addition of poly(ethylene
glycol) (PEG). We expect that a new generation of dPG-NH2
with improved pharmacokinetics will lead to improved selective
accumulation in the tumor site. Here, we demonstrated that
miRNA replacement provides a new therapeutic concept for the
treatment of GBM. The broad anti-oncogenic activity of
miR-34a holds the prospect of creating a new therapeutic
modality that is effective against heterogeneous tumors such
as GBM.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.nano.2016.05.016.References
1. Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, Pytel P.
Molecular heterogeneity in glioblastoma: therapeutic opportunities and
challenges. Semin Oncol 2011;38:243-53.
2. Weller M. Novel diagnostic and therapeutic approaches to malignant
glioma. Swiss Med Wkly 2011;141:w13210.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer
RC, et al. Effects of radiotherapy with concomitant and adjuvant
temozolomide versus radiotherapy alone on survival in glioblastoma in a
randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Lancet Oncol 2009;10:459-66.
4. Ong BY, Ranganath SH, Lee LY, Lu F, Lee HS, Sahinidis NV, et al.
Paclitaxel delivery from PLGA foams for controlled release in post-
surgical chemotherapy against glioblastoma multiforme. Biomaterials
2009;30:3189-96.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn
MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352:987-96.
6. Friedman GK, Spiller SE, Harrison DK, Fiveash JB, Reddy AT.
Treatment of children with glioblastoma with conformal radiation,
temozolomide, and bevacizumab as adjuncts to surgical resection.
J Pediatr Hematol Oncol 2013;35:e123-6.
7. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon 2nd
JE, Marcello J, et al. The addition of bevacizumab to standard radiation
therapy and temozolomide followed by bevacizumab, temozolomide,
and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 2011;
17:4119-24.
8. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, et al.
Phase II study of bevacizumab plus temozolomide during and after
radiation therapy for patients with newly diagnosed glioblastoma
multiforme. J Clin Oncol 2011;29:142-8.
9. Holland EC. Glioblastoma multiforme: the terminator. Proc Natl Acad
Sci U S A 2000;97:6242-4.
10. Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular
understanding of glioblastoma. J Neuro-Oncol 2012;108:11-27.11. Shi L, Chen J, Yang J, Pan T, Zhang S, Wang Z. MiR-21 protected
human glioblastoma U87MG cells from chemotherapeutic drug
temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and
caspase-3 activity. Brain Res 2010;1352:255-64.
12. Li Y, Li W, Yang Y, Lu Y, He C, Hu G, et al. MicroRNA-21 targets
LRRFIP1 and contributes to VM-26 resistance in glioblastoma multi-
forme. Brain Res 2009;1286:13-8.
13. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential
tumor suppressor by inducing apoptosis in neuroblastoma cells.Oncogene
2007;26:5017-22.
14. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M,
Lee KH, et al. Transactivation of miR-34a by p53 broadly influences
gene expression and promotes apoptosis. Mol Cell 2007;26:745-52.
15. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N,
Moskovits N, et al. Transcriptional activation of miR-34a contributes to
p53-mediated apoptosis. Mol Cell 2007;26:731-43.
16. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen
A, et al. Differential regulation of microRNAs by p53 revealed by
massively parallel sequencing: miR-34a is a p53 target that induces
apoptosis and G1-arrest. Cell Cycle 2007;6:1586-93.
17. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A
microRNA component of the p53 tumour suppressor network. Nature
2007;447:1130-4.
18. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive
miR-34a induces senescence-like growth arrest through modulation of
the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A
2007;104:15472-7.
19. Dijkstra MK, van Lom K, Tielemans D, Elstrodt F, Langerak AW, van't
Veer MB, et al. 17p13/TP53 deletion in B-CLL patients is associated
with microRNA-34a downregulation. Leukemia 2009;23:625-7.
20. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. miR-34a inhibits
migration and invasion by down-regulation of c-Met expression in
human hepatocellular carcinoma cells. Cancer Lett 2009;275:44-53.
21. Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, Gel B, et al.
miR-34a as a prognostic marker of relapse in surgically resected non-
small-cell lung cancer. Carcinogenesis 2009;30:1903-9.
22. Li WB, Ma MW, Dong LJ, Wang F, Chen LX, Li XR. MicroRNA-34a
targets notch1 and inhibits cell proliferation in glioblastoma multiforme.
Cancer Biol Ther 2011;12:477-83.
23. Ji Q, Hao X, Zhang M, TangW, YangM, Li L, et al. MicroRNAmiR-34
inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009;
4:e6816.
24. Greenberg E, Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg
R, et al. Regulation of cancer aggressive features in melanoma cells by
microRNAs. PLoS One 2011;6:e18936.
25. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The
microRNAmiR-34a inhibits prostate cancer stem cells and metastasis by
directly repressing CD44. Nat Med 2011;17:211-5.
26. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, et al. Downregulation of
CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett
2008;582:1564-8.
27. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, et al. The
MYCNoncogene is a direct target ofmiR-34a.Oncogene 2008;27:5204-13.
28. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al.
MicroRNA-34a inhibits glioblastoma growth by targeting multiple
oncogenes. Cancer Res 2009;69:7569-76.
29. Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, et al.
microRNA-34a is tumor suppressive in brain tumors and glioma stem
cells. Cell Cycle 2010;9:1031-6.
30. Wan K, Ebert B, Voigt J, Wang Q, Dai Y, Haag R, et al. In vivo tumor
imaging using a novel RNAi-based detection mechanism. Nanomedicine
2012;8:393-8.
31. Fischer W, Calderon M, Schulz A, Andreou I, Weber M, Haag R.
Dendritic polyglycerols with oligoamine shells show low toxicity and
high siRNA transfection efficiency in vitro. Bioconjug Chem 2010;21:
1744-52.
2214 P. Ofek et al / Nanomedicine: Nanotechnology, Biology, and Medicine 12 (2016) 2201–221432. Ahmed F, Pakunlu RI, Brannan A, Bates F, Minko T, Discher DE.
Biodegradable polymersomes loaded with both paclitaxel and doxorubicin
permeate and shrink tumors, inducing apoptosis in proportion to
accumulated drug. J Control Release 2006;116:150-8.
33. Ofek P, Fischer W, Calderon M, Haag R, Satchi-Fainaro R. In vivo
delivery of small interfering RNA to tumors and their vasculature by
novel dendritic nanocarriers. FASEB J 2010;24:3122-34.
34. Sunder A, Kramer M, Hanselmann R, Mulhaupt R, Frey H. Molecular
Nanocapsules Based on Amphiphilic Hyperbranched Polyglycerols.
Angew Chem 1999;38:3552-5.
35. Sunder A, Heinemann J, Frey H. Controlling the growth of polymer
trees: concepts and perspectives for hyperbranched polymers. Chemistry
2000;6:2499-506.
36. Kramer M, Stumbe JF, GrimmG, Kaufmann B, Kruger U,Weber M, et al.
Dendritic polyamines: simple access to newmaterials with defined treelike
structures for application in nonviral gene delivery. Chembiochem 2004;5:
1081-7.
37. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al.
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is
associated with CpG island methylation in colorectal cancer. Cancer Res
2008;68:4123-32.
38. Bae Y, Yang T, Zeng HC, Campeau PM, Chen Y, Bertin T, et al.
miRNA-34c regulates Notch signaling during bone development. Hum
Mol Genet 2012;21:2991-3000.
39. Du R, Sun W, Xia L, Zhao A, Yu Y, Zhao L, et al. Hypoxia-induced
down-regulation of microRNA-34a promotes EMT by targeting the
Notch signaling pathway in tubular epithelial cells. PLoS One 2012;7:
e30771.
40. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al.
p53-mediated activation of miRNA34 candidate tumor-suppressor
genes. Curr Biol 2007;17:1298-307.
41. Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur
GM, et al. A functional screen identifies miR-34a as a candidate
neuroblastoma tumor suppressor gene. Mol Cancer Res 2008;6:
735-42.
42. Merdan T, Callahan J, Petersen H, Kunath K, Bakowsky U, Kopeckova
P, et al. Pegylated polyethylenimine-Fab' antibody fragment conjugates
for targeted gene delivery to human ovarian carcinoma cells. Bioconjug
Chem 2003;14:989-96.
43. Engelberg H. Plasma heparin levels. Correlation with serum cholesterol
and low-density lipoproteins. Circulation 1961;23:573-7.44. Huang Z, Yang Y, Jiang Y, Shao J, Sun X, Chen J, et al. Anti-tumor
immune responses of tumor-associated macrophages via toll-like
receptor 4 triggered by cationic polymers. Biomaterials 2013;34:746-55.
45. Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and
treatment. Pharmacol Ther 2015.
46. Bradley D, Rees J. Updates in the management of high-grade glioma.
J Neurol 2014;261:651-4.
47. Tumilson CA, Lea RW, Alder JE, Shaw L. Circulating microRNA
biomarkers for glioma and predicting response to therapy. Mol
Neurobiol 2014;50:545-58.
48. Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A,
Campani V, et al. Mir-34: a new weapon against cancer? Mol Ther
Nucleic acids 2014;3:e194.
49. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK,
Weiss GJ, et al. First-in-humans trial of an RNA interference therapeutic
targeting VEGF and KSP in cancer patients with liver involvement.
Cancer Discov 2013;3:406-17.
50. Organ SL, Tsao MS. An overview of the c-MET signaling pathway.
Ther Adv Med Oncol 2011;3:S7-S19.
51. Li B, He H, Tao BB, Zhao ZY, Hu GH, Luo C, et al. Knockdown of
CDK6 enhances glioma sensitivity to chemotherapy. Oncol Rep 2012;
28:909-14.
52. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate
control and signal integration in development. Science 1999;284:770-6.
53. Stockhausen MT, Kristoffersen K, Poulsen HS. The functional role of
Notch signaling in human gliomas. Neuro-Oncology 2010;12:199-211.
54. Rehman AO, Wang CY. Notch signaling in the regulation of tumor
angiogenesis. Trends Cell Biol 2006;16:293-300.
55. Fischer I, Gagner JP, LawM, Newcomb EW, Zagzag D. Angiogenesis in
gliomas: biology and molecular pathophysiology. Brain Pathol 2005;
15:297-310.
56. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed
cell death. Cancer Res 1999;59:1693s-700s.
57. Wick W, Wagner S, Kerkau S, Dichgans J, Tonn JC, Weller M. BCL-2
promotes migration and invasiveness of human glioma cells. FEBS Lett
1998;440:419-24.
58. Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D, et al.
Inhibition of vessel permeability by TNP-470 and its polymer conjugate,
caplostatin. Cancer Cell 2005;7:251-61.
59. Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities.
RNA 2010;16:2043-50.
